Lexicon (LXRX) Pharmaceuticals announced it will present data from two studies related to LX9851, its investigational compound for obesity and weight loss, at Obesity Week 2024, November 3-5, 2024, at the Henry Gonzalez Convention Center in San Antonio, Texas. Preclinical in vivo efficacy data from the first study showed that treatment with LX9851 resulted in significant reductions in weight, food intake and fat mass in diet-induced obese, DIO, mice. Among other important findings, LX9851 mitigated weight regain following discontinuation of the GLP-1 analogue semaglutide. On Day 28, fat and lean body mass were measured by DEXA. All treatments with LX9851 resulted in a reduction in fat mass compared to vehicle control. The greatest weight reduction with no significant effect on lean body mass was observed when LX9851 was combined with semaglutide. The combination therapy also resulted in additive positive effects on liver steatosis and related study end points.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- LXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lexicon price target lowered to $6 from $10 at H.C. Wainwright
- FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
- FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
- Lexicon announces new analysis of Phase 3 SCORED trial